The Daily Biotech Pulse: Merck’s Keytruda Clinches Another FDA Win, KemPharm Close To NDA Filing For ADHD Drug

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling The Peaks

(Biotech stocks hitting 52-week highs on April 11)

  • Edap Tms SA (NASDAQ: EDAP)

Down In The Dumps

(Biotech stocks hitting 52-week lows on April 11)

  • ABIOMED, Inc. (NASDAQ: ABMD)
  • Alcon AG (NYSE: ALC) (was down for a second straight session after spinning off from Novartis AG (NYSE: NVS) Tuesday)
  • Acorda Therapeutics Inc (NASDAQ: ACOR)
  • Akorn, Inc. (NASDAQ: AKRX)
  • Concert Pharmaceuticals Inc (NASDAQ: CNCE)
  • Helius Medical Technologies Inc (NASDAQ: HSDT)
  • OUTLOOK THERAPEUTICS, INC. (NASDAQ: OTLK)(announced pricing of common stock and warrant offering)
  • Precision BioSciences Inc (NASDAQ: DTIL)
  • Revance Therapeutics Inc (NASDAQ: RVNC)
  • Scpharmaceuticals Inc (NASDAQ: SCPH)
  • Vaxart Inc (NASDAQ: VXRT)
  • Teligent Inc (NASDAQ: TLGT)
  • Teva Pharmaceutical Industries Ltd (NYSE: TEVA)

Stock In Focus

Merck's Keytruda Okayed For Advanced Lung Cancer

Merck & Co., Inc. (NYSE: MRK) announced FDA approval for its Keytruda as a monotherapy for first-line treatment of patients with stage 3 non-small cell lung cancer, who cannot undergo surgery or chemoradiation, or metastatic NSCLC patients and whose tumors express PD-L1 with no EGFR or ALK genomic tumor aberrations.

The company said the approval was granted based on the Phase 2 KEYNOTE-042 trial.

Keytruda has been a major driver for …

Full story available on Benzinga.com

The post The Daily Biotech Pulse: Merck’s Keytruda Clinches Another FDA Win, KemPharm Close To NDA Filing For ADHD Drug appeared first on MrTopStep.com.